HCW Biologics Inc
HCWB4.130USD
+0.005+0.12%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.64MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über HCW Biologics Inc Unternehmen
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Unternehmensinformationen
BörsenkürzelHCWB
Name des UnternehmensHCW Biologics Inc
IPO-datumJul 20, 2021
CEODr. Hing C. Wong, Ph.D.
Anzahl der mitarbeiter36
WertpapierartOrdinary Share
GeschäftsjahresendeJul 20
Addresse2929 N Commerce Pkwy
StadtMIRAMAR
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33025
Telefon19548422024
Websitehttps://hcwbiologics.com/
BörsenkürzelHCWB
IPO-datumJul 20, 2021
CEODr. Hing C. Wong, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
509.96K
+27.06%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
+280.84%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+20.23%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
509.96K
+27.06%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
+24.49%
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
+280.84%
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+20.23%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Aug 1
Aktualisiert: Fri, Aug 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Wong (Hing C)
25.87%
Byam (Rebecca)
2.18%
Garrett (Scott T)
1.29%
Avantax Planning Partners, Inc
0.35%
The Vanguard Group, Inc.
0.31%
Other
69.99%
Aktionäre
Aktionäre
Anteil
Wong (Hing C)
25.87%
Byam (Rebecca)
2.18%
Garrett (Scott T)
1.29%
Avantax Planning Partners, Inc
0.35%
The Vanguard Group, Inc.
0.31%
Other
69.99%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
30.09%
Investment Advisor
0.92%
Investment Advisor/Hedge Fund
0.51%
Research Firm
0.02%
Other
68.46%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
40
619.84K
31.44%
+87.21K
2025Q1
40
480.61K
42.86%
-46.33K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
2023Q3
33
19.17M
53.35%
-2.58K
2023Q2
33
22.70M
63.26%
-3.42M
2023Q1
32
22.37M
62.46%
-3.36M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Wong (Hing C)
509.96K
25.87%
+108.61K
+27.06%
May 16, 2025
Byam (Rebecca)
43.01K
2.18%
+8.46K
+24.49%
May 12, 2025
Garrett (Scott T)
25.50K
1.29%
+18.81K
+280.84%
May 16, 2025
Avantax Planning Partners, Inc
6.99K
0.35%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
6.08K
0.31%
+5.14K
+545.33%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.92K
0.3%
+1.38K
+30.23%
Mar 31, 2025
Flowers (Lee)
5.72K
0.29%
+962.00
+20.23%
May 08, 2025
Winer (Gary M)
4.08K
0.21%
+3.65K
+858.82%
May 16, 2025
Cresset Asset Management, LLC
3.30K
0.17%
--
--
Mar 31, 2025
Greene (Rick Scott)
2.07K
0.1%
+962.00
+87.14%
May 12, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
